Lilly Launches Sarafem; Bayer Nimotop SAH Indication Expanded
This article was originally published in Pharmaceutical Approvals Monthly
Lilly’s Sarafem brand of fluoxetine was launched August 14 as the first prescription treatment in the U.S. for premenstrual dysphoric disorder (PMDD). The product, which is marketed for PMDD in 15 other countries, cleared FDA July 6
You may also be interested in...
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class